BioSpace News Archive

Biotech Beach

Agendia Presents New Data on the Biological Characteristics of Patients within Extreme Low Risk and High Risk MammaPrint Subgroups at the European Society for Medical Oncology (ESMO)

Agendia Inc. will present new data from their on-going clinical research at the European Society for Medical Oncology Congress 2019, taking place from September 27 to October 1 in Barcelona, Spain.

September 29, 2019
·
4 min read
Drug Development

ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO

ImmunoGen, Inc. announced initial safety and overall response data from the Phase 1b FORWARD II triplet cohort evaluating mirvetuximab in combination with carboplatin and Avastin® in patients with recurrent, platinum-sensitive ovarian cancer at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain.

September 29, 2019
·
5 min read
Pharm Country

Novartis Kisqali® delivers consistently superior overall survival - MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients

Novartis announced results from the MONALEESA-3 trial, which showed Kisqali® (ribociclib) achieved statistically significant improvement in overall survival (OS).

September 29, 2019
·
12 min read
Biotech Bay

Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients

Edwards Lifesciences Corporation announced new data demonstrating early and sustained health status advantages for severe aortic stenosis patients at low surgical risk treated with the Edwards SAPIEN 3 valve.

September 29, 2019
·
4 min read
Drug Development

Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal

Kinoxis Therapeutics Pty Ltd has been awarded a major grant from the US National Institutes of Health, National Institute on Drug Abuse (NIH/NIDA).

September 29, 2019
·
4 min read
Job Trends

Elevar Announces Results from the ANGEL trial, a study of Monotherapy Rivoceranib (Apatinib) in Late-Stage Gastric Cancer Patients

Elevar Therapeutics announced data from the ANGEL trial, a randomized phase 3 study of rivoceranib plus best supportive care in patients with gastric or gastroesophageal junction cancer who have failed at least 2 prior lines of therapy.

September 29, 2019
·
4 min read
Biotech Bay

Late-Breaking Data Shows Abbott’s MitraClip™ is Cost Effective, Increases Life Expectancy and Improves Quality of Life

New late-breaking data at TCT 2019 demonstrate that Abbott’s MitraClip™ is cost-effective for heart failure patients with significant secondary mitral regurgitation compared to guideline-directed medical therapy alone

September 29, 2019
·
7 min read
Drug Development

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

Interim Results from Pivotal Neoadjuvant/Adjuvant Phase 3 KEYNOTE-522 Trial Presented for the First Time at ESMO 2019 Congress During Presidential Symposium

September 29, 2019
·
34 min read
Drug Development

Isofol Announces Presentation on the Global Phase 3 Study of Arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress

Isofol Medical AB, announced a poster presentation on the ongoing global Phase 3 AGENT clinical study in patients with metastatic colorectal cancer.

September 29, 2019
·
3 min read
New Major Order From China

Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the third quarter of approximately SEK 4,8 million.

September 29, 2019
·
1 min read